Autolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a research note issued to investors on Monday morning, Marketbeat Ratings reports. They currently have $7.60 target price on the stock, up from their previous target price of $7.00.

A number of other equities analysts have also weighed in on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $10.15.

Autolus Therapeutics Trading Down 5.1 %

Shares of NASDAQ AUTL opened at $2.80 on Monday. The company has a market cap of $745.05 million, a price-to-earnings ratio of -2.31 and a beta of 2.04. The stock has a 50-day moving average price of $3.83 and a two-hundred day moving average price of $3.96. Autolus Therapeutics has a 12 month low of $2.74 and a 12 month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the company posted ($0.26) earnings per share. On average, sell-side analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently modified their holdings of AUTL. SG Americas Securities LLC purchased a new position in Autolus Therapeutics in the 1st quarter worth approximately $127,000. EntryPoint Capital LLC grew its stake in shares of Autolus Therapeutics by 113.6% in the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after acquiring an additional 11,456 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Autolus Therapeutics by 117.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock worth $21,532,000 after acquiring an additional 1,824,592 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter worth $78,765,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.